Introduction
Jun is a component of the activator protein 1 (AP-1) transcription factor complex (Vogt, 2001) . Together with other AP-1 proteins like Fos and related proteins, it belongs to the large family of basic region leucine zipper (bZip) proteins, characterized by a leucine zipper dimerization domain and an adjacent basic region DNA-binding domain. In Jun, the bZip structure is located at the C-terminus of the molecule; the Nterminal region contains a multipartite transactivation domain (TAD). Jun can form homodimers but it mainly heterodimerizes with various other bZip proteins. The DNA target sequences of the dimers are the 12-O-tetradecanoylphorbol-13-acetate (TPA) response element (TRE, ATGACTCAT) and the related cyclic AMP response element (CRE, ATGACGTCAT). The transcriptional regulatory activity of Jun is positively controlled by the c-Jun N-terminal kinase (JNK), which phosphorylates serine residues 63 and 73 in the Nterminal region of Jun (Derijard et al., 1994) . The retroviral version of Jun (v-Jun) carries a deletion within that N-terminal region (delta deletion) and consequently fails to interact with JNK; it is a constitutive transcriptional activator (Black et al., 1994) .
The mechanism by which Jun induces oncogenic transformation is not known. Since functional domains mediating dimerization, DNA binding and transactivation are required for oncogenicity, it is generally assumed that transformation is the result of aberrant transcriptional regulation (Shaulian and Karin, 2001) . The properties of an N-terminal domain deletion mutant of Jun, TAM-67, are consistent with this view; this mutant can competitively suppress transactivation of AP-1 and functions as dominant negative for cell transformation (Brown et al., 1994; Young et al., 1999; Ludes-Meyers et al., 2001) . However, transactivation from Jun target promoters does not appear to be the only factor that determines oncogenicity. Deletion analysis of the cellular Jun (c-Jun) in the region of the delta domain revealed mutants that are poor transactivators yet potent transformers and some that are strongly transactivating yet only marginally oncogenic (Bos et al., 1990; Havarstein et al., 1992) . Experiments with GCN4 also call into question the exclusive role of TRE-directed transactivation in oncogenic transformation. GCN4 is a yeast bZip transcription factor closely homologous to Jun in its DNA-binding domain (Vogt et al., 1987) . The DNA-binding specificity of GCN4 is very similar to that of Jun, but the function of GCN4 in yeast is related to the nutritional status (Hinnebusch, 1984; Lucchini et al., 1984; Arndt and Fink, 1986) whereas Jun regulates a wide variety of cellular functions; most of them are related to cell growth and survival (reviewed in Oliphant et al., 1989; Vogt, 2001) . In vertebrate cells, GCN4 strongly activates transcription from a TRE carrying reporter, yet fails to induce oncogenic transformation (Oliviero et al., 1992) . In contrast, a chimeric construct in which the N-terminal TAD of GCN4 is replaced with that of Jun is able to transform cells (Oliviero et al., 1992) . This observation suggests that the spectrum of target genes addressed by a transcription factor is not determined exclusively by the specificity of DNA binding but is also affected by proteinprotein interactions that involve the TAD. Diverse TADs may be able to mediate such interactions. Chimeric Jun constructs in which the indigenous TAD is exchanged for that of the herpes viral protein VP16 or of the human estrogen receptor (ER) are oncogenic (Schuur et al., 1993; Kruse et al., 1997) , suggesting effectiveness of a heterologous TAD in transformation. The spectrum of transformation-related targets is also influenced by the dimerization partner of Jun. Mutants of Jun that preferentially pair with members of the Fos family induce anchorage-but not growth factor-independence, whereas mutated Jun that selectively associates with the bZip protein activating transcription factor-2 (ATF2) causes growth factor-independence but fails to support anchorage-independent growth .
The ability of Jun to form functionally distinct heterodimers with various bZip proteins complicates the identification and characterization of downstream targets, because the level of Jun dimerization partners in the cell cannot be controlled. The qualitative and quantitative composition of the cellular Jun heterodimer population is largely unknown, and under these conditions the relative effect of any Jun heterodimer on cell growth is difficult to assess. In addition, AP-1 transcription factors can associate with unrelated transcriptional regulators to form specific functional complexes. For instance, the Jun-Fos heterodimer can interact with the nuclear factor of activated T cells (NF-AT) family transcription factors, and the ternary complexes preferentially recognize composite-binding sequences (Macian et al., 2001) .
For an analysis of the oncogenic functions of AP-1 proteins, it is clearly desirable to work with constructs that can only homodimerize. GCN4 fulfills this condition, although by itself it has no transforming ability. Therefore, we have constructed chimeric molecules, retaining the GCN4 bZip domain and attaching the VP16 TAD either as a replacement for that of GCN4, or in addition to the GCN4 TAD. Several of these constructs induce oncogenic transformation in cultures of chicken embryo fibroblasts (CEF). All transforming constructs activate transcription of the TRE-luciferase reporter but do not upregulate every previously identified Jun target. A comparison of target spectra between various oncogenic constructs should facilitate identification of target genes that are relevant for transformation.
Results

Comparison of the DNA-binding specificities of GCN4 and Jun
The DNA target sequences of GCN4 and Jun have been determined previously by selection from a pool of random oligonucleotides and polymerase chain reaction (PCR) amplification (Oliphant et al., 1989; Kataoka et al., 1994) . Both transcription factors have been reported to recognize TRE and CRE sequences, but the two proteins have not been compared directly in the same system. We have performed such a comparison using bacterially produced proteins that consist of the DNA-binding domain of GCN4 or v-Jun fused to maltose-binding protein (MBP) to permit affinity purification. Electrophoretic mobility shift assays of the purified proteins are shown in Figure 1 . As expected, Figure 1 Comparative analysis of DNA-binding specificities of vJun and GCN4. The two bZip proteins prepared as fusion proteins with MBP were used in gel mobility shift assays with a series of oligonucleotide probes. The nucleotide sequence of only the middle, unique part of the probes is shown at the top. Nucleotide matches with the consensus-binding sequence of Jun are underlined. Probes #11 and #19 include a complete TRE-type consensus sequence for Jun and GCN4 (ATGACTCAT). Probes #1, #17 and #3 contain two to three mismatches from the TRE-type consensus. Probes #12 and #20 contain a complete CRE-type consensus for them (ATGACGTCAT). Probes #2, #18 and #4 are mutated versions of the CRE-type consensus sequences. The shifted bands are marked by lines on the right-hand side of the figure. Mulitple shifted bands observed with MBP-fused GCN4 protein are likely to be derived from degradation products of the fusion protein Transcriptional activation induced by the GCN4-derived constructs Figure 2 shows the structures of the GCN4 fusion proteins constructed in this study. All have the NDGCN4 sequence in common, consisting of the basic region and leucine zipper of GCN4 plus short adjacent N-terminal and C-terminal sequences. In two of the chimeric proteins, the NDGCN4 sequence is supplemented N-terminally or C-terminally with the TAD derived from the herpes simplex viral protein VP16. Two additional constructs make use of almost the entire GCN4 coding sequence, adding the VP16 TAD at either end. We expressed these molecules in two different ways to evaluate their transactivation potential. In the first experiment (Experiment 1), the constructs were expressed by the pHyg-EF-2 vector in transient transfection assays in CEF with 3 Â #11/pRBGP as a reporter construct. The results (Figure 2) show that v-Jun is a moderate transactivator in CEF; the value for GCN4 is about equal to that of Jun. NDGCN4, with its TAD deleted, does not activate transcription. The four constructs containing the VP16 TAD are all strong transactivators; the ones that retain the GCN4 TAD are the most active. These results show that the VP16 TAD can function in CEF in conjunction with a GCN4 DNA binding and dimerization domain. In another transactivation experiment (Experiment 2), the GCN4-derived molecules were expressed from the pRV-9 avian retroviral vector. CEF were infected with recombinant viruses that express the GCN4-derived molecules. The next day, the reporter and internal control plasmids were transfected into the virus-infected cells. In this case, viral interference does not allow multiple infection with the recombinant viruses. Even in fully infected cells, the GCN4-derived molecules are probably expressed from one or very few copies of the provirus genome. With this expression system, v-Jun did not increase AP-1 activity of the cells as has been reported previously (Hawker et al., 1993; Hussain et al., 1998) . GCN4 and NDGCN4 molecules showed marginal transactivation and very weak transrepression activities, respectively. Under the same assay conditions, the four forms of GCN4-derived molecules that include the VP16 TAD induced 1.5-to 2-fold transactivation of the reporter, indicating that these constructs are effectively expressed from the viral vector and the GCN4-derived molecules are active.
Cellular transformation induced by GCN4-derived chimeras
The constructs shown in Figure 2 , subcloned into pRV-9, were transfected into CEF. The cells were then either overlaid with nutrient agar to observe cell transformation, or they were kept in liquid media for harvest of the released infectious pRV-9 retroviruses which were then used in further assays for focus and agar colony formation. Representative results are depicted in Figures 3 and 4. Wild-type GCN4 failed to transform, consistent with published data obtained in mouse cell cultures (Oliviero et al., 1992) . As expected, the NDGCN4 deletion, lacking a TAD, also failed to induce oncogenic transformation. The fusion constructs VP16-NDGCN4 and NDGCN4-VP16, in which the GCN4 TAD is replaced by that of VP16, were active in transformation assays, inducing both focus and agar colony formation. The efficiency of transformation for both constructs was comparable to that of Jun. However, the foci induced by the fusion proteins were smaller and less distinct than those of Jun ( Figure 3 ). The agar colonies were also smaller than Jun-induced colonies ( Figure 4 ). Considering the near identity of the DNA-binding specificities of Jun and GCN4, these observations suggest that homodimers of the N-terminally deleted GCN4 with the VP16 TAD can mimic the effect of Jun on cellular anchorage and growth factor requirements and induce aberrant growth, probably by deregulating target genes that are also affected by Jun. The two constructs that combine the entire GCN4 coding sequence with the TAD of VP16 were unexpectedly nontransforming, despite their high activity in transcriptional reporter assays. These constructs contain both GCN4 and VP16 TADs; their failure to induce foci or agar colonies suggests a negative effect of the GCN4 TAD on transformation. As controls for the requirement of dimerization and DNA binding in transformation induced by GCN4 constructs, we placed inactivating mutations in the leucine zipper and DNAbinding domain of GCN4, resulting in the constructs VP16-NDGCN4-L2P and VP16-NDGCN4-K22E. These mutants were nontransforming ( confirming the need for dimerization and DNA binding in the oncogenic process established for Jun (Turner and Tjian, 1989) .
Growth behavior of CEF infected with the GCN4 constructs
Accelerated growth and growth factor-independence are important criteria of cell transformation. In order to confirm the transformed phenotype of CEF expressing the NDGCN4 chimeras, we examined the replication of the cells in high or low serum liquid culture conditions. CEF infected with the recombinant viruses were replated at low cell density (1.0 Â 105 cells/60 mm plate). The cells were then incubated in high serum (10% calf serum þ 4% chicken serum) or low serum (0.6% calf serum) liquid medium. The numbers of the cells were counted at several time points after seeding. v-Jun stimulated cell replication in both culture conditions ( Figure 6 ). The three nontransforming GCN4-derived constructs GCN4, VP16-GCN4 and GCN4-VP16 (not shown) failed to affect cell replication at high or low serum conditions. The transforming constructs VP16, NDGCN4 and NDGCN4-VP16 (not shown) stimulated cell replication under both conditions, although they were less potent than Jun. These results suggest that homodimers of an artificial AP-1 factor can induce growth factor-independence. This conclusion appears at variance with previous studies that had suggested dimerization with ATF-2 as a requirement for the induction of the growth factor-independent cellular phenotype. Growth factor-independent replication was also observed with a Jun-GCN4 chimera, in which the zipper domain of Jun was replaced by that of GCN4 (Hartl and Vogt, 1992; Castellazzi et al., 1993) . CEF transformed by this construct replicated vigorously at low serum concentration (data not shown).
Construction of an inducible cell transformation system
We next constructed an inducible cell transformation system. Fusion molecules containing the bZip domain of Jun and the hormone-binding domain of the human ER induce cell transformation in a b-estradiol-dependent manner (Kruse et al., 1997) . The hormone-binding domain of ER regulates cellular localization of the Figure 7 summarizes structures and cell transforming abilities of the ER-GCN4 fusion molecules. All three constructs contain the hormone-binding domain of the human ER and the bZip domain of GCN4. Two of the molecules also contain the TAD of VP16. These constructs were subcloned into the pRV-9 retroviral vector, and tested for cell transforming ability. The NDGCN4-ER-VP16 construct showed estradiolcontrolled cell transforming ability on CEF. Although this construct contains the nonconditional VP16 TAD, treatment with 4-HT did not induce cell transformation, suggesting that the chimeric construct depends on the transactivation activity of the hormone-binding domain.
Expression of Jun target genes in CEF transformed by the VP16-GCN4 fusion proteins
Target genes of transforming Jun have been described in several published studies. Most of these targets are upregulated in Jun-transformed cells; a few are downregulated (Vogt, 2001) . Some of the upregulated targets, if overexpressed by themselves, affect the cellular phenotype, inducing a partial transformation, and some downregulated targets can revert Jun-induced transformation if they are upregulated (Hartl and Bister, 1998; Bader et al., 2001; Cohen et al., 2001; Hartl et al., 2001) . Presumably, a combination of known and unknown targets exists that will induce full transformation if appropriately deregulated. This combination of relevant targets still remains to be determined. We have tested the expression of six Jun target genes and of the POU(3.1) gene (Studler et al., 1993) which was recently identified as a gene induced by the NDGCN4-ER-VP16 fusion construct (Nishizawa and Vogt, 2002 unpubl.) in CEF transformed by VP16-NDGCN4, Jun or Maf. The Maf protein was originally identified as the oncogene product of the avian oncogenic retrovirus AS42 (Nishizawa et al., 1989) . It is a bZip protein addressing TRE-and CRE-related sequences (Kataoka et al., 1994) . Recent results suggest that Jun and Maf are likely to share downstream target genes for the induction of cellular transformation (Kataoka et al., 2001) . CEF expressing GCN4 or vector alone were included as controls. The results of Northern analyses are combined in Figure 8 . Among the genes examined, cyclin D1 (Mechta et al., 1997) was not clearly affected by the oncoproteins. The POU(3.1) gene was induced by GCN4 and VP16-NDGCN4, but was not activated by Jun or Maf. Expression of the POU(3.1) gene was also efficiently activated by nontransforming GCN4-derived constructs, VP16-GCN4 and GCN4-VP16 (data not shown). All other targets were overexpressed in Juntransformed CEF and, except for the Jun-induced LIM protein, RIL (Fu et al., 2000) , they were also overexpressed in Maf-transformed CEF. In contrast, VP16-NDGCN4 induced only glutaredoxin (Goller et al., 1998) and RIL, but did not lead to an increase in mRNA levels of heparin-binding epidermal growth factor (HB-EGF) (Fu et al., 1999) , MAP kinase phosphatase-2 (MKP-2) or VJT-35 (Fu et al., 2000) . These results show that there is only partial overlap in the target genes of Jun and of the VP16-NDGCN4 construct. Assuming that these oncoproteins induce transformation by the same mechanism, the transformation-relevant genes would have to be sought in the group of overlapping targets. Effect of GCN4 derivatives on the growth curve of CEF. CEF were infected with the recombinant viruses and were seeded at low cell density in high or low serum medium. Cell numbers were counted as indicated
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Discussion
Jun and GCN4 share a basic architecture, but in their native environments they fulfill different functions. In both proteins, the bZip domain is located at the C terminus; the N-terminal half contains the TAD. TRE and CRE are the consensus DNA-binding sites for GCN4 as well as Jun, but since the DNA contact surfaces of these proteins are not identical, they may have preferences for different variants of the consensus sequence or differ in their recognition of sequence contexts. In vertebrate cells, Jun, together with Fos and their related proteins, converts growth signals into patterns of gene expression. Jun is also involved in apoptosis and development (Basuyaux et al., 1997; Wisdom, 1999) . GCN4 in yeast regulates the amino-acid synthesizing machinery (Hinnebusch, 1984; Lucchini et al., 1984; Arndt and Fink, 1986) . These functional differences are probably determined both by the composition of the target spectra and the proteinprotein interactions engaging the TADs of Jun and of GCN4.
In this study, we have taken advantage of the fact that GCN4, in eukaryotic cells, can form only homodimers and therefore cannot be modulated by interaction with endogenous bZip proteins. In contrast, Jun interacts not only with endogenous bZip factors but also with structurally unrelated factors, for example, NF-AT, Ets or Smad family proteins, to form a variety of complexes (Basuyaux et al., 1997; Zhang et al., 1998; Cell transformation by artificial AP-1 M Nishizawa et al Liberati et al., 1999; Chinenov and Kerppola, 2001; Macian et al., 2001) . This promiscuity complicates the analysis of Jun function because the composition and amounts of intracellular Jun interacting factors are not known but must affect Jun function. Several studies have sought to eliminate this difficulty by substituting the Jun dimerization domain with one allowing only homodimer formation (Hartl and Vogt, 1992; Castellazzi et al., 1993) . Chimeras in which the zipper domain of Jun is replaced with that of GCN4 form only homodimers. The transforming activity of these constructs suggests that heterodimerization between Jun and other bZip proteins is not required for transformation (Bos et al., 1990; Huguier et al., 1998) . In order to eliminate possible interactions with partner proteins that bind to Jun outside the zipper sequence, we have replaced all Jun sequences in our constructs. The VP16 sequence is not homologous to Jun and, outside the zipper region, GCN4 shows only low homology to Jun. Jun modulating proteins are therefore highly unlikely to affect these constructs. Jun and the artificial activator protein constructs probably have only the elementary interactions with DNA target sequences and with the transcriptional machinery in common. The transforming activity of these very different proteins suggests that these elementary interactions are both necessary and sufficient for oncogenicity. The current studies are also in agreement with previous work demonstrating that not only can the Jun TAD transduce an oncogenic signal when addressed to TRE or CRE promoters but so can the TAD of VP16 (Schuur et al., 1993) . Proteins that bind to the TAD of Jun or Fos may be different from the proteins that bind to the TAD of VP16. The artificial AP-1 dimer may, despite binding to the AP-1 site of DNA, not always behave like a true AP-1 complex. However, transforming ability indicates that the GCN4-derived molecules can induce target genes relevant for cell transformation. For the AP-1 related oncoproteins, transforming ability and transactivation activity in transient transfection are not correlated. Highly activating but nontransforming constructs have been identified in this and in previous studies, and poor activators can be fully oncogenic (Bos et al., 1990; Havarstein et al., 1992) . The reporter assays that measure transactivation do not reflect the transcriptional regulatory functions that are critical for oncogenicity.
Recent experiments on the mediator complex that connects enhancer and promoter activities may shed light on these observations. In yeast, GCN4 and VP16 require different mediator subunits for activated transcription of specific genes (Myers et al., 1999) . This suggests that the TADs of GCN4 and VP16, both of which are acidic, may operate by different mechanisms and interact with overlapping but nonidentical spectra of downstream targets (Jackson et al., 1996) . The TADs of GCN4 and of VP16 also interact with the chromatin remodeling complex SWI/SNF (Liberati et al., 1999) . These TADs could conceivably differ in the specificity of these interactions as well. In the constructs carrying both the GCN4 and VP16 TADs, the GCN4 component appears to have a negative effect on the oncogenicity of the protein, which may result from competition for some critical downstream component. The chimeric construct may have conformational properties that prevent interaction with downstream mediators, or the two nontransforming constructs may accumulate at lower levels in CEF. The GCN4 TAD could trigger rapid degradation or prevent efficient translation. In transient transfection assays, one of the nontransforming constructs, VP16-GCN4, showed the highest transactivation activity, but the same construct showed a lower transactivation activity than transforming constructs if the chimeric molecules were expressed by virus infection (Figure 2 ). Attempts to estimate expression levels of the GCN4 chimeras by Western blotting were not successful. A VP16 antibody that reacts with other VP16 fusion proteins failed to detect the transforming or nontransforming GCN4 chimeric proteins in cell extracts, either because of subliminal levels of expression or because of rapid degradation of these proteins. The fact that all four GCN4 chimeras function as transcriptional activators shows that they are synthesized in the cell and suggests that instability in extracts may make them difficult to detect in Western assays.
Studies with Jun have shown that the dimerization partners can tilt the response of the cell to either anchorage-or growth factor-independence . The GCN4-derived constructs described here are capable of inducing both types of aberrant growth as homodimers. These results suggest that anchorage and growth factor-independence do not necessarily result from the complementary function of different bZip heterodimers but can be induced by a single homodimer.
The central problem in understanding oncogenic transformation is the identification of relevant targets. Novel technologies including DNA and oligonucleotide arrays that allow genome-wide screens for genes differentially regulated in transformed cells produce long lists of potential targets. Techniques are now needed that can reduce these large numbers of differentially regulated genes, identifying those targets that play essential roles in transformation. For bZip transcription factors, we propose a comparative approach, using diverse transforming constructs that address TRE and CRE sites. Assuming that transformation induced by these different bZip proteins shares essential elements, we would seek critical genes among those targets that are differentially regulated by all transforming constructs. The comparison of previously identified Jun targets in CEF transfected with various transforming and nontransforming bZip constructs carried out in this study offers an initial, limited illustration of the general principle. As summarized in Figure 9 , glutaredoxin is upregulated by all transforming constructs and also by GCN4; it would qualify as a target that is necessary but not sufficient for transformation. HB-EGF, upregulated by Jun and Maf and capable of inducing a partially transformed phenotype in CEF, is not affected by VP16-NDGCN4 and therefore probably not indispensable for transformation. The mammalian HB-EGF is regulated by a Jun-Ets complex which could explain the ineffectiveness of VP16-NDGCN4, assuming that VP16-NDGCN4 cannot interact with Ets while Maf may have this ability (McCarthy et al., 1997) . VJT-35 and MKP-2 show patterns of expression that are similar to that of HB-EGF. POU(3.1) is only activated by GCN4 and VP16-NDGCN4. RIL is affected by GCN4, VP16-NDGCN4 and Jun but not by Maf; it may therefore also not be essential for transformation. These data show that transcription factors that nominally address the same DNA sequence do not have identical target spectra and the list of relevant genes can be substantially reduced by focusing on shared targets. The ability to consolidate target lists becomes particularly important for the analysis of expression profiles obtained by microarray techniques.
Regulatable transforming constructs allow determining the time course of target activation or repression. They can also aid in the discrimination between direct targets and indirect targets. The latter are controlled by products of direct targets; they therefore fail to be differentially regulated in the presence of inhibitors of protein synthesis such as cycloheximide. Regulatable oncogenes also offer significant advantage in microarray analysis.
Materials and methods
Plasmid construction
We constructed two expression vectors for this study. pRV-9 is a derivative of avian replication competent retroviral vector, RCAS(A) (Hughes et al., 1987) . The pRV-9 vector was constructed on a pUC-9 vector backbone in place of RCAS(A) backbone plasmid, pBR322, resulting in higher plasmid yield. This vector also has multiple cloning sites providing enhanced flexibility for plasmid construction. Another vector constructed in this study is the expression vector pHyg-EF-2, which contains the hygromycin resistance gene as a selectable marker, the strong eukaryotic promoter of the human elongation factor 1a derived from the pEF-BOS plasmid (Mizushima and Nagata, 1990) , and a pUC plasmid backbone. In order to avoid autoregulation of the constructs, the functional AP-1 site in the elongation factor 1a promoter (Wakabayashi-Ito and Nagata, 1994) was eliminated by sitedirected mutagenesis. The sequences of these two vectors have been submitted to the GenBank DNA database (pRV-9: AF484679; pHyg-EF-2: AF483548).
For subcloning of the GCN4 coding region, we added an MluI linker onto both ends of the sequence. The resulting MluI fragment was subcloned into the MluI site of pRV-9 or the BssHII site of pHyg-EF-2.
An N-terminal deletion mutant of GCN4, NDGCN4, was constructed by digestion of GCN4 with XbaI followed by treatment with the Klenow fragment of DNA polymerase I. A synthetic ATG sequence was added to the blunt end to serve an initiator codon. In the resulting NDGCN4 construct, the N-terminal 167 amino-acid residues of GCN4 are replaced with the initiator methionine codon.
The coding sequence for the strong TAD of the herpes simplex virus VP16 protein, consisting of the carboxy-terminal 78 amino acids, was excised and was linked to adapter sequences by PCR amplification. The 5 0 -end adapter includes a methionine codon for translational initiation. The amplified fragment was then subcloned into the pUC plasmid and used as a cassette for the following construction steps. The VP16-NDGCN4 fusion gene was constructed by replacing the Nterminal 167 amino acids of GCN4 with an initiator codon and the VP16 TAD. In VP16-GCN4, the N-terminal 10 amino acids of GCN4 were replaced with an initiator codon, the VP16 fragment, and two amino acids (Met-Thr) encoded by the adapter. NDGCN4-VP16 and GCN4-VP16 were also made by fusion of the VP16 sequence, utilizing synthetic oligonucleotide adapters, to the C-terminus of NDGCN4 or GCN4, respectively. These two constructs include a tri-peptide sequence (Gly-Val-Met) at the fusion site and four additional amino acids (Met-Thr-Leu-Thr) at the C-terminus; these are derived from the synthetic adapters.
A 0.75 kilobase BspHI-BsaHI fragment that includes almost all of human ER hormone-binding domain was excised from the HE14 plasmid and was used in chimeric constructs (Kumar et al., 1986) . To the 3 0 end of the excised fragment, we added double-stranded synthetic oligonucleotides, which provide a translational termination codon and several restriction sites. The structure of this oligonucleotide and the encoded aminoacid sequence are shown below.
SphI BspLU11I XbaI MluI
The resulting BspHI-MluI fragment includes 'region E' of ER that is essential and sufficient for estrogen-dependent nuclear localization (Kumar et al., 1986) . To make the NDGCN4-ER construct, the BspHI-MluI fragment was fused to the C-terminus of NDGCN4 using a synthetic linker. The linker sequence adds two additional amino acids (Gly-Val) at the fusion site. NDGCN4-ER-VP16 was constructed by replacing the C-terminal three amino-acid residues of NDGCN4-ER with the VP16 TAD. VP16-NDGCN4-ER was constructed from VP16-NDGCN4 and NDGCN4-ER. All constructs were subcloned into the pRV-9 expression vector for cell transformation assays.
Gel mobility shift assays
The bZip domain of the GCN4 protein was synthesized as a fusion protein with the Esherichia coli MBP, using the -c vector (New England Biolabs) . A restriction fragment of GCN4, which encodes the C-terminal 114 amino-acid residues, was recloned into the polylinker of pMAL-c. Construction of a vector that expresses MBP-fused v-Jun protein has been described previously (Kataoka et al., 1994) . Purification of the MBP-fused proteins and gel mobility shift assays were also performed as described before (Kataoka et al., 1994) .
Cell culture and transient transfection
Primary CEF cultures were prepared from embryos supplied by SPAFAS (Preston, CT, USA) and were maintained as described previously (Vogt, 1969) . For the recovery of infectious viruses, pRV-9 and its derived constructs were transfected onto CEF cells by the DMSO transfection method (Kawai and Nishizawa, 1984) . Estradiol treatment of CEF was performed as described previously (Kruse et al., 1997) . Growth curve experiments were performed as described . For transient transfection assays, we used 3 Â #11/pRBGP-luciferase, which contains triplicated TRE sequences, the b-globin basal promoter and the firefly luciferase gene, as a reporter plasmid, and the Renilla luciferase/pHyg-EF-2 construct as an internal control. For the cotransfection experiment, the pHyg-EF-2 expression vector constructs of the GCN4 derivatives were transfected into CEF along with the reporter and internal control plasmids, using the Lipofectamine Plus transfection reagent (Invitrogen, Carlsbad, CA, USA). Cell lysates were prepared 24 h after transfection, and were assayed in the Dual-luciferase assay system (Promega, Madison, WI, USA). In another transactivation assay experiment, the GCN4-derived molecules were expressed from the avian viral vector pRV-9. CEF were seeded and infected with the recombinant viruses, which express the GCN4-derived molecules. The next day, the cells were transfected with the reporter and internal control plasmids using the Lipofectamine Plus transfection reagent. In this case, the cells were incubated for 2 more days (48 h) before preparing cell lysate for the luciferase assay.
Northern blots
Total RNA was isolated using the RNA STAT-60 reagent (Tel-Test, Friendswood, TX, USA). The RNA samples were then separated in 1% formaldehyde-agarose gels and were blotted onto Hybond-N nylon membranes (Amersham Pharmacia, Piscataway, NJ, USA). 32 P-labeling of probes and hybridization were performed as described before (Fu et al., 2000) .
Abbreviations bZip, basic region leucine zipper; AP-1, activator protein 1; TAD, transactivation domain; TPA, 12-O-tetra-decanoylphorbol-13-acetate; TRE, TPA-responsive element; CRE, cyclic-AMP-responsive element; JNK, c-Jun-N-terminal kinase; ATF2, activating transcription factor-2; NF-AT, nuclear factor of activated T cells; CEF, chicken embryo fibroblasts; PCR, polymerase chain reaction; ER, estrogen receptor; MBP, maltose-binding protein; HB-EGF, heparin-binding epidermal growth factor; MKP-2, MAP kinase phosphatase-2.
